Jun. 16 at 10:13 PM
$HURA "We are excited to be the first company to advance a VISTA-inhibiting antibody for investigation in hematologic cancers, targeting molecularly defined subsets of AML, including those with NPM1 and in the future, FLT3-ITD mutations, two of the most common mutations present in approximately 60-70% of patients with AML.”
“We also plan to include patients with relapsed/refractory (r/r) high-risk myelodysplasia (MDS), where VISTA expression, like in AML, generally correlates with low response rates and poor survival outcomes.”
"Currently, there are no approved or effective treatment options for these patient populations, representing a significant unmet medical need."
- Dr. James Bianco, President and CEO of TuHURA Biosciences.
https://www.prnewswire.com/news-releases/tuhura-biosciences-files-investigational-new-drug-application-for-evaluation-of-the-tbs-2025-vista-inhibiting-antibody-in-molecularly-defined-subsets-of-aml-and-other-blood-related-cancers-302799770.html
